3 results
Approved WMOPending
Primary: To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy (see Definitions).Subjects will be…
Approved WMOCompleted
To evaluate the effects on ovarian function with the NOMAC/E2 COC in a group of women aged 18-35 years.
Approved WMOCompleted
• To assess contraceptive efficacy, vaginal bleeding patterns (cycle control),general safety and acceptability of the NOMAC-E2 COC in a large group ofwomen aged 18-50 years.